Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.
Several other research firms have also issued reports on DNLI. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research note on Monday, December 16th. Robert W. Baird started coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 target price on the stock. Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Finally, Jefferies Financial Group upped their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.
Read Our Latest Analysis on DNLI
Denali Therapeutics Stock Up 0.7 %
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the company posted ($0.72) EPS. Equities analysts anticipate that Denali Therapeutics will post -2.73 EPS for the current year.
Insider Activity
In other Denali Therapeutics news, insider Alexander O. Schuth sold 15,558 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the sale, the insider now directly owns 178,066 shares in the company, valued at approximately $5,325,954.06. The trade was a 8.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now directly owns 111,056 shares in the company, valued at $3,331,680. The trade was a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,518 shares of company stock valued at $1,469,382 over the last three months. Insiders own 7.90% of the company’s stock.
Institutional Trading of Denali Therapeutics
Several large investors have recently added to or reduced their stakes in DNLI. FMR LLC raised its holdings in Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after purchasing an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Denali Therapeutics by 63.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock worth $109,223,000 after buying an additional 1,451,770 shares during the period. Wellington Management Group LLP increased its stake in Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock worth $312,491,000 after buying an additional 903,683 shares in the last quarter. Millennium Management LLC raised its holdings in Denali Therapeutics by 58.7% during the second quarter. Millennium Management LLC now owns 619,929 shares of the company’s stock valued at $14,395,000 after acquiring an additional 229,313 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Denali Therapeutics by 13.8% in the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock valued at $36,076,000 after acquiring an additional 149,939 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Read More
- Five stocks we like better than Denali Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Using the MarketBeat Dividend Tax Calculator
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What is a Stock Market Index and How Do You Use Them?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.